Finanzas de Ocular Therapeutix Inc (OCUL)OCULOcular Therapeutix Inc

Evaluating the bottom line, Ocular Therapeutix, Inc. maintains a gross margin of 85.08%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -609.34%, while the net margin is -584.51%. These profitability ratios, combined with a Return on Equity (ROE) of -72.99%, provide a clear picture of how effectively OCUL converts its operational activities into shareholder value.

In the context of the broader market, OCUL competes directly with industry leaders such as ETON and PCRX. With a market capitalization of $1.46B, it holds a significant position in the sector. When comparing efficiency, OCUL's gross margin of 85.08% stands against ETON's 67.61% and PCRX's 69.60%. Such benchmarking helps identify whether Ocular Therapeutix, Inc. is trading at a premium or discount relative to its financial performance.

Ocular Therapeutix has reported negative net income consistently, with a net income of -$88,612,000 in Q1 2026 and a gross margin of 85.08% in Q2 2026, indicating some operational efficiency despite losses.